ATE530540T1 - Pyrimidonverbindungen als gsk-3-inhibitoren - Google Patents
Pyrimidonverbindungen als gsk-3-inhibitorenInfo
- Publication number
- ATE530540T1 ATE530540T1 AT07789659T AT07789659T ATE530540T1 AT E530540 T1 ATE530540 T1 AT E530540T1 AT 07789659 T AT07789659 T AT 07789659T AT 07789659 T AT07789659 T AT 07789659T AT E530540 T1 ATE530540 T1 AT E530540T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- gsk
- compounds
- pyrimidone compounds
- pyrimidone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82326706P | 2006-08-23 | 2006-08-23 | |
PCT/IB2007/002390 WO2008023239A1 (en) | 2006-08-23 | 2007-08-13 | Pyrimidone compounds as gsk-3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE530540T1 true ATE530540T1 (de) | 2011-11-15 |
Family
ID=38670755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07789659T ATE530540T1 (de) | 2006-08-23 | 2007-08-13 | Pyrimidonverbindungen als gsk-3-inhibitoren |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100292205A1 (de) |
EP (1) | EP2057141B1 (de) |
JP (1) | JP2010501540A (de) |
KR (1) | KR20090052884A (de) |
CN (1) | CN101528729A (de) |
AT (1) | ATE530540T1 (de) |
AU (1) | AU2007287319A1 (de) |
CA (1) | CA2661334C (de) |
ES (1) | ES2373587T3 (de) |
IL (1) | IL197080A0 (de) |
MX (1) | MX2009001913A (de) |
NO (1) | NO20090783L (de) |
WO (1) | WO2008023239A1 (de) |
ZA (1) | ZA200901037B (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009036132A1 (en) | 2007-09-11 | 2009-03-19 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
EP2138488A1 (de) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen |
AR076014A1 (es) * | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
JP5442852B2 (ja) * | 2009-08-13 | 2014-03-12 | 田辺三菱製薬株式会社 | タウプロテインキナーゼ1阻害剤としてのピリミドン誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
CN103180312B (zh) * | 2010-09-13 | 2016-01-20 | 大塚制药株式会社 | 用于治疗或预防因血清素、去甲肾上腺素或多巴胺的神经传导的降低所导致的紊乱的杂环化合物 |
MX339873B (es) | 2011-02-28 | 2016-06-15 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
CN103958502B (zh) | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
NZ624068A (en) | 2011-12-31 | 2016-09-30 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
ES2857649T3 (es) | 2012-03-01 | 2021-09-29 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
AR092253A1 (es) | 2012-08-27 | 2015-04-08 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
WO2014159356A1 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
KR20230019500A (ko) | 2014-09-03 | 2023-02-08 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법 |
AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beigene, Ltd. | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
EP3400286A1 (de) | 2016-01-08 | 2018-11-14 | Massachusetts Institute Of Technology | Herstellung von differenzierten enteroendokrinen zellen und insulinproduzierenden zellen |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
JP6993056B2 (ja) | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのpd-1アンタゴニスト及びraf阻害剤の組合せ |
ES2896938T3 (es) * | 2016-11-28 | 2022-02-28 | Bristol Myers Squibb Co | Inhibidores de GSK-3 |
JP7109446B2 (ja) | 2016-12-30 | 2022-07-29 | フリークエンシー セラピューティクス インコーポレイテッド | 幹細胞/前駆支持細胞の自己複製を誘導するための1h-ピロール-2,5-ジオン化合物およびその使用方法 |
MA50413A (fr) | 2017-10-19 | 2020-08-26 | Amgen Inc | Dérivés de benzimidazole et leurs utilisations |
EP3837352A1 (de) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Zusammensetzungen und verfahren zur erzeugung von haarzellen durch hochregulieren von jag-1 |
WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬 |
CN113666878A (zh) * | 2021-08-27 | 2021-11-19 | 宁夏常晟药业有限公司 | 一种5-溴-2-氯嘧啶-4-羧酸甲酯的合成方法 |
WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136099A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidonderivate als GSK3beta-Hemmer |
EP1136483A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidonderivate |
WO2001070727A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
EP1136489A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperidin-1-yl]pyrimidinonderivate |
EP1136491A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Heteroarylalkylamino]pyrimidonderivate |
EP1136482A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer |
EP1136493A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate |
EA007576B1 (ru) * | 2001-09-21 | 2006-12-29 | Мицубиси Фарма Корпорейшн | Производные 3-замещенных 4-пиримидонов |
US7572793B2 (en) * | 2001-09-21 | 2009-08-11 | Mitsubishi Tanabe Pharma Corporation | 3-Substituted-4-pyrimidone derivatives |
MXPA05006394A (es) * | 2002-12-16 | 2007-04-16 | Mitsubishi Pharma Corp | Derivados de 4-pirimidona 3-sustituida. |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
US20070117818A1 (en) * | 2004-02-04 | 2007-05-24 | Masaichi Hasegawa | Pyrimidinone compounds useful as kinase inhibitors |
TW200621760A (en) * | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
NZ554722A (en) * | 2004-09-29 | 2010-07-30 | Mitsubishi Tanabe Pharma Corp | 6-(Pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
-
2007
- 2007-08-13 ES ES07789659T patent/ES2373587T3/es active Active
- 2007-08-13 EP EP07789659A patent/EP2057141B1/de not_active Not-in-force
- 2007-08-13 JP JP2009525121A patent/JP2010501540A/ja not_active Withdrawn
- 2007-08-13 WO PCT/IB2007/002390 patent/WO2008023239A1/en active Application Filing
- 2007-08-13 AT AT07789659T patent/ATE530540T1/de not_active IP Right Cessation
- 2007-08-13 US US12/438,198 patent/US20100292205A1/en not_active Abandoned
- 2007-08-13 MX MX2009001913A patent/MX2009001913A/es not_active Application Discontinuation
- 2007-08-13 AU AU2007287319A patent/AU2007287319A1/en not_active Abandoned
- 2007-08-13 CN CNA2007800394073A patent/CN101528729A/zh active Pending
- 2007-08-13 CA CA2661334A patent/CA2661334C/en not_active Expired - Fee Related
- 2007-08-13 KR KR1020097005783A patent/KR20090052884A/ko not_active Application Discontinuation
-
2009
- 2009-02-13 ZA ZA200901037A patent/ZA200901037B/xx unknown
- 2009-02-17 IL IL197080A patent/IL197080A0/en unknown
- 2009-02-18 NO NO20090783A patent/NO20090783L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20090783L (no) | 2009-03-13 |
ZA200901037B (en) | 2010-04-28 |
WO2008023239A1 (en) | 2008-02-28 |
ES2373587T3 (es) | 2012-02-06 |
US20100292205A1 (en) | 2010-11-18 |
EP2057141A1 (de) | 2009-05-13 |
JP2010501540A (ja) | 2010-01-21 |
CN101528729A (zh) | 2009-09-09 |
MX2009001913A (es) | 2009-03-06 |
CA2661334A1 (en) | 2008-02-28 |
IL197080A0 (en) | 2009-11-18 |
KR20090052884A (ko) | 2009-05-26 |
EP2057141B1 (de) | 2011-10-26 |
AU2007287319A1 (en) | 2008-02-28 |
CA2661334C (en) | 2011-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
DE602004013563D1 (de) | Rantagonisten | |
UA115983C2 (uk) | Інгібітори днк-пк | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
MX2012004114A (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
ATE456571T1 (de) | Proteasom-hemmer und verwendungsverfahren dafür | |
NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
EA201170832A1 (ru) | Пуриновые соединения | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |